Grufity logo
Grufity logo
ENVB

ENVB - Enveric Biosciences, Inc. Stock Price, Fair Value and News

$1.55+0.12 (+8.39%)
Market Closed as of 31 Jul 2026, 04:00 pm ET

Price Targets

ENVB Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ENVB Price Action

Last 7 days

20.2%

Last 30 days

3.3%

Last 90 days

-61.1%

Trailing 12 Months

-89.4%

ENVB RSI Chart

ENVB Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ENVB Valuation

Market Cap

5.7M

Price/Earnings (Trailing)

-0.69

Price/Sales (Trailing)

0.24

EV/EBITDA

-0.71

Price/Free Cashflow

-0.71

ENVB Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

ENVB Fundamentals

ENVB Revenue

Revenue (TTM)

35.4M

ENVB Earnings

Earnings (TTM)

-8.2M

Earnings Growth (Yr)

25.24%

Earnings Growth (Qtr)

25.55%

ENVB Profitability

Operating Margin

20.66%

EBT Margin

-23.22%

Return on Equity

-162.44%

Return on Assets

-148.88%

Free Cashflow Yield

-140.3%

ENVB Investor Care

Shares Dilution (1Y)

1687.57%

Diluted EPS (TTM)

-23.35

Revenue & Growth

How Enveric Biosciences, Inc. generates revenue and covers its expenses, based on the latest reported earnings.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2021----
202038.8M36.1M35.4M-
201942.6M42.6M41.1M39.9M
201847.3M46.1M44.2M43.0M
201741.5M47.1M49.5M48.6M
201623.0M25.7M31.3M36.1M
201516.8M16.8M16.9M20.4M
20146.1M11.5M--
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Enveric Biosciences, Inc.

ENVB
Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead program is EB-373, an active metabolite of psilocybin, which is in Phase 1 clinical trials for the treatment of anxiety disorders; EVM-301 for treating mental health; and EV104 CBD + Celecoxib conjugate for treating osteoarthritis. The company also developing cannabinoid-infused topical product for the treatment of radiodermatitis; and cannabinoid and COX-2 inhibitor conjugation that is in pre-clinical stage for the treatment of OA/acute pain. Enveric Biosciences, Inc. is headquartered in Naples, Florida.
 CEO
 WEBSITEenveric.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES25

Enveric Biosciences, Inc. Frequently Asked Questions

ENVB is the stock ticker symbol of Enveric Biosciences, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Jul 31 2026, market cap of Enveric Biosciences, Inc. is 5.71 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Jul 31 2026, ENVB's PE ratio (Price to Earnings) is -0.69 and Price to Sales (PS) ratio is 0.24. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ENVB PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Enveric Biosciences, Inc. has provided -0.832 (multiply by 100 for percentage) rate of return.